Pfizer Forecasts $9.7B Savings Through 2029 After Earnings Beat
Pfizer expects $9.7 billion in total net savings from cost cuts through 2029 to offset declining COVID revenue and support growth, trimming admin and sales/marketing expenses 3% in the first half while raising R&D 12% year over year. The quarter included a net loss driven by acquisition charges and a $3.8B impairment tied to experimental lung therapy, and sales guidance rose to $60.5–$62.5B.